* Citius Pharmaceuticals Inc CTXR.OQ CTXR.O is expected
to show no change in quarterly revenue when it reports
results on May 11 (estimated).
* Refinitiv's mean analyst estimate for Citius
Pharmaceuticals
Inc is for a loss of 7 cents per share. For the same quarter
last year, the company reported a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $6, above its last closing price
of $1.04.
This summary was machine generated May 9 at 16:07 GMT. All
figures in US dollars unless otherwise stated